Implementation of social distancing policies correlates with significant reduction in SARS-CoV-2 transmission

According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded with significant reductions in transmission of the SARS-CoV-2 virus and reduced community mobility, both in the U.S. and globally, providing evidence that social distancing is a useful tool in preventing further spread of COVID-19.

Read more

Study sheds light on fatty acid’s role in “chemobrain” and multiple sclerosis

A study led by The University of Texas MD Anderson Cancer Center has found that myelin is surprisingly dynamic, a discovery that has implications for treatment of multiple sclerosis and a type of myelin damage caused by some chemotherapy drugs, often referred to as “chemobrain.”

Read more

Study provides new understanding of mitochondria genome with potential for new avenues of treatment for multiple cancers

A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.

Read more

Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.

Read more

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival

Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.

Read more

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

Read more